ArticleThe New England journal of medicine2017
Pembrolizumab for Advanced Urothelial Carcinoma.
Article in The New England journal of medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Switch Maintenance Therapy for Metastatic Urothelial Carcinoma.Bladder cancer (Amsterdam, Netherlands) · 2022Pooled it
- Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS).BMC cancer · 2021Trial
- Improved oncolytic and immunostimulatory activity of the spontaneousMolecular therapy. Oncology · 2026Article
- The Impact of Design Misspecifications on Survival Outcomes in Cancer Clinical Trials.Cancers · 2025Article
- Article
- Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project.Clinical & experimental metastasis · 2024Observational
- Outcomes with atezolizumab in metastatic urothelial cancer: real-world data from a single institution.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Review
- Efficacy of Antibody Drug Conjugates Alone and in Combination with other Agents in Metastatic Urothelial Carcinoma: A Scoping Review.Bladder cancer (Amsterdam, Netherlands) · 2024Article
- PD-L1 expression and correlation with outcome in muscle-invasive and metastatic urothelial carcinoma: review and critical discussion.Frontiers in oncology · 2024Review
- Sensitive, non-immunogenicCell stress · 2023Article
- Monocyte chemoattractant protein 1 as a potential biomarker for immune checkpoint inhibitor-associated neurotoxicity.Cancer medicine · 2023Article
- Assessment of PD-L1 Status in Urothelial Cancer.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Metastatic urothelial carcinoma harboringWorld journal of clinical cases · 2022Article
- Prognostic Impact of CD36 Immunohistochemical Expression in Patients with Muscle-Invasive Bladder Cancer Treated with Cystectomy and Adjuvant Chemotherapy.Journal of clinical medicine · 2022Article
- A review of the biology and therapeutic implications of cancer-associated fibroblasts (CAFs) in muscle-invasive bladder cancer.Frontiers in oncology · 2022Review
- Panels and models for accurate prediction of tumor mutation burden in tumor samples.NPJ precision oncology · 2021Article
- Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade.Cancer discovery · 2020Article
- Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors.Cancer discovery · 2020Article
- Angiogenesis related gene expression significantly associated with the prognostic role of an urothelial bladder carcinoma.Translational andrology and urology · 2020Article
- A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma.British journal of cancer · 2020Article
Corrections and comments
- Comment on
- Comment on
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
28591526What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.